Both in Pharmaceuticals
Atrium Therapeutics vs Zentalis Pharmaceuticals
Over the past year RNA returned −87.5% and ZNTL returned +23.6%; their daily moves had a correlation of 0.04.
RNA −87.5% ZNTL +23.6%Growth of $1, one year, split-adjusted
| Metric | RNA | ZNTL |
|---|---|---|
| Price | $8.72 | $1.78 |
| Market cap | $149.2M | $168.5M |
| Today | +1.99% | −3.78% |
| 1 month | +9.4% | −36.0% |
| 6 months | −32.5% | −56.5% |
| Year to date | −87.9% | +31.9% |
| 1 year | — | +18.7% |
| Revenue growth (YoY) | −21.9% | — |
| Gross margin | 100.0% | — |
| Net margin | −672.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.1× | — |
| Net cash | $263.9M | $174.6M |
| Dividend yield | — | — |
| Volatility (60d) | 65.8% | 71.0% |
| Short % of float | 22.9% | 9.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).